Next Article in Journal
New Neurons in the Postnatal Olfactory System: Functions in the Healthy and Regenerating Brain
Previous Article in Journal
The Role of Mind Wandering During Incubation in Divergent and Convergent Creative Thinking
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Brain Sciences
Volume 15
Issue 6
10.3390/brainsci15060596
brainsci-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Investigating the Relationship Between Hopelessness, Alexithymia, Mind Wandering, Rumination, and Clinical Features in Patients with Bipolar Disorder

by
Andrea Aguglia
1,2,*,†,
Tommaso Cerisola
1,†,
Martina Rimondotto
1,
Simona Iannini
1,
Francesco Bruni
1,
Francesca Bigiotti
1,
Alessandra Costanza
3,4,
Mario Amore
1,
Andrea Amerio
1,2 and
Gianluca Serafini
1,2
1
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Section of Psychiatry, University of Genoa, Largo Paolo Daneo 3, 16132 Genoa, Italy
2
IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy
3
Department of Psychiatry, Faculty of Medicine, Geneva University (UNIGE), 24 Rue du General-Dufour, 1211 Geneva, Switzerland
4
Department of Psychiatry, Faculty of Biomedical Sciences, University of Italian Switzerland (USI), via Buffi 13, 6900 Lugano, Switzerland
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Brain Sci. 2025, 15(6), 596; https://doi.org/10.3390/brainsci15060596
Submission received: 29 April 2025 / Revised: 23 May 2025 / Accepted: 29 May 2025 / Published: 2 June 2025
(This article belongs to the Section Neuropsychiatry)
Versions Notes

Abstract

Background/Objectives: The understanding of the mechanisms involved in the etiopathogenesis and maintenance of Bipolar Disorder (BD) should be a priority to identify potential early clinical markers that could help in improving treatment strategies and prevention. The aim of this study was to investigate the potential correlation between hopelessness, alexithymia, mind wandering, and rumination in patients with a primary diagnosis of BD, evaluating whether these psychopathological aspects could negatively affect bipolar illness. Methods: A semi-structured interview was used to collect sociodemographic and clinical characteristics. Several psychometric tools were administered: the Beck Hopelessness Scale; Toronto Alexithymia Scale; Rumination Response Scale; Mind Wandering Questionnaire; Mind Wandering: Deliberate; Mind Wandering: Spontaneous; and the Daydreaming Frequency Scale. Results: Patients with high levels of hopelessness have a greater number of psychiatric and medical comorbidities and are more frequently on polypharmacotherapy. Additionally, patients with high levels of hopelessness show a greater likelihood of having attempted suicide during their lifetime. The presence of alexithymia is associated with longer hospitalization and psychiatric comorbidities. Higher levels of rumination correlate with a greater number of psychiatric and medical comorbidities, and with the presence of residual symptoms. Mind wandering is associated with the presence of medical comorbidities and residual symptoms. Conclusions: Hopelessness, alexithymia, mind wandering, and rumination should be identified as important proxies of impaired subjective well-being that should be carefully monitored because they could further worsen the clinical course of BD and suicidal risk in this vulnerable population.

1. Introduction

Bipolar Disorder (BD) is a severe, chronic, and cyclic psychiatric disorder characterized by recurrent affective episodes [1], affecting approximately 2–3% of the general population and representing a leading cause of disability worldwide [2].
Patients with BD have a higher prevalence of both psychiatric and medical comorbidities compared to the general population [3], and this could represent a potential risk factor contributing to the frequent use of long-life complex pharmacological treatment [4,5,6]. A primary diagnosis of BD is also associated with premature mortality, due to higher rates of suicidal behaviors and cardio-vascular–metabolic comorbidities [7,8,9]. BD can be differentiated into type I and II, according to the presence of manic and hypomanic episodes, respectively. Based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM 5-TR), the distinction between manic and hypomanic episodes considers different clinical aspects, such as a duration of a minimum of seven and four days for manic and hypomanic episodes, respectively; a negative impact on functioning; and the presence of psychotic, confusional, or pantoclastic symptoms in a manic episode. It should be noted that hypomanic and major depressive episodes can be present in both disorders. Both BD type I and II have significant negative impacts on quality of life and require ongoing personalized clinical management.
Understanding the mechanisms involved in the etiopathogenesis and maintenance of BD should be a priority in order to identify potential early clinical markers that could help in improving treatment and prevention strategies. Therefore, a deeper understanding and analysis of particular clinical features, such as alexithymia, hopelessness, mind wandering, and rumination could be helpful for clinicians, especially when assessing suicidal risk and comorbidities. Hopelessness, defined as a subjective emotion characterized by feelings of powerlessness and pessimism about the future, is a transdiagnostic clinical dimension accepted as an indicator of high suicide risk not only in neurological and psychiatric patients but also in the general population [10,11,12]. A study on outpatients with a primary diagnosis of BD suggested that hopelessness may be considered a trait factor conferring greater vulnerability for suicidal behaviors [13] and, recently, insomnia symptomatology has been considered a potential mediator of this correlation [14]. On the other hand, alexithymia is a psychological condition characterized by difficulties in understanding and describing one’s emotions and distinguishing feelings from bodily arousal signals. High levels of alexithymia lead to a limited capacity for imagination and symbolic thinking, with negative consequences on general and social functioning in BD, due to objective difficulties in the expression of emotions through symbols or metaphors, contributing to worsening outcomes and a greater risk of suicidality [15,16,17]. Recently, an association between childhood emotional abuse and alexithymia with bipolar symptoms and suicidal ideation, mediated by emotional dysregulation, has been demonstrated [18,19,20]. In addition, rumination is defined as a response to a depressed mood that involves focusing on the possible meanings, causes, and consequences of depressive symptoms passively and repeatedly, tending to keep people fixed on their problems and feelings without acting [21,22,23]. Rumination worsens emotional dysregulation and affective lability in all mood bipolar recurrences, aggravating both depressive and (hypo)manic phases and also contributing to suicidal behaviors and potentially dangerous behaviors, respectively [22,24]. Finally, mind wandering is defined as a moment when attention shifts from the perceptual world (i.e., the ongoing task) to focus on the internal world (one’s thoughts and feelings) [25]. Both rumination and mind wandering are associated with negative emotions, compromising patients’ mental well-being and leading to maladaptive mental states as low self-esteem and negative cognitive loops which could further elicit or worsen suicidal ideation [26,27,28,29].
Therefore, the aim of this study was to investigate the potential correlation between hopelessness, alexithymia, mind wandering, and rumination in patients with a primary diagnosis of BD, evaluating whether these psychopathological aspects could negatively affect bipolar illness. Our main hypothesis is that feelings of hopelessness, alexithymia, mind wandering, and rumination may, indeed, predict a worsening of clinical and psychopathological bipolar course, with a higher prevalence of medical or psychiatric comorbidities and suicidal behaviors.

2. Materials and Methods

2.1. Study Design and Participants

A cross-sectional study was conducted on one hundred and seventy-one patients with a primary diagnosis of BD, according to the criteria of the DSM 5-TR [1]. All the participants were consecutively admitted to the Section of Psychiatry, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), IRCCS Ospedale Policlinico San Martino, University of Genoa (Italy), from September 2022 to April 2024.
An in-depth description of the study was given to all potential participants, explaining the study objectives and procedures in detail with the opportunity to ask questions about the goals of the study.
The study was designed in agreement with the guidelines from the Declaration of Helsinki, as revised in 2013 [30], and was approved by the Local Research Ethical Committee.

2.2. Assessment

A semi-structured interview, used in previously published research articles [6,31,32], was administered to collect the following sociodemographic and clinical characteristics: age, gender, duration of illness and hospitalization, age of onset, presence of psychotic and residual symptoms, suicidal ideation, current or lifetime suicidal attempts, psychiatric and medical comorbidities, use of complex pharmacological treatment, and ongoing psychotherapy treatment.
Furthermore, each participant completed a battery of psychometric tools, including the Beck Hopelessness Scale (BHS), Toronto Alexithymia Scale (TAS-20), Ruminative Response Scale (RRS-22), and Mind Wandering Questionnaire (MWQ). The validated Italian versions of each scale were used for this study, and each psychometric tool was presented and explained to the patients. They were informed that the data gathered with these tools could be useful in recognizing a subgroup of patients who could potentially benefit from a specific non-pharmacological personalized treatment approach.
-
The BHS is a 20-item self-administered questionnaire designed to measure hopelessness, its different dimensions, and more specifically, feelings about the future, loss of motivation, and expectations [33].
-
The TAS-20 is a self-report scale consisting of 20 items measuring difficulty in identifying feelings, including the differentiation between emotional states and bodily sensations; difficulty in describing feelings to others; and a constricted imaginative process with an externally oriented cognitive style. Scores equal to or greater than 61 indicate the presence of alexithymia [34].
-
The RRS is a 22-item self-administered questionnaire commonly used to evaluate ruminative tendencies, consisting of three factors: brooding (e.g., ‘[how often do you] think “why do I have problems other people don’t have?”’), depression (e.g., ‘[how often do you] think about how sad you feel’), and self-reflection (e.g., ‘[how often do you] go someplace alone to think about your feelings’) [35,36]. Items are rated on a scale ranging from 1 to 4 (almost never, sometimes, often, and almost always), with higher scores indicating worse ruminative symptoms.
-
The MWQ is a 5-item scale designed to assess the frequency and propensity of mind wandering, both in its deliberate or spontaneous form. Each item is rated on a Likert scale from 1 (almost never) to 6 (almost always) [37]. The items on this scale are written in simple language to allow for a good applicability adolescents as well as adults [38].

2.3. Statistical Analysis

Statistical analyses were performed using R software version 4.3.1 (V.4.3.1; R package meta, R Foundation for Statistical Computing, Vienna, Austria). The statistical significance was set at p < 0.05. Continuous and categorical variables were presented as means and standard deviations (SDs) or frequency and percentage, respectively.
Linear correlations between sociodemographic data and the results of the clinical assessments were evaluated using Spearman’s Rank Correlation. The patients were also divided into two subgroups depending on their specific bipolar diagnosis (BD type I and II). To further investigate a potential correlation between the variables of interest and patients’ diagnoses, two-sample t-test analysis was performed for continuous variables. The Smirnov–Grubbs test was performed to confirm the absence of outliers. As this was an exploratory study aimed at identifying potential associations, no correction for multiple comparisons was applied. The findings should be considered hypothesis-generating and warrant further confirmation in future longitudinal studies using larger samples and correction procedures.

3. Results

3.1. Sociodemographic and Clinical Characteristics

The total sample included 171 patients with a primary diagnosis of BD, of which 86 (50.3%) were females. The mean age was 48 years (SD ± 14). A total of 70 (40.9%) patients had a diagnosis of BD type I, whereas 101 (59.1%) had a diagnosis of BD type II. For all patients, the mean age of onset of BD was 27 years (SD ± 11), while the mean duration of illness was 21 years (SD ± 13). The mean duration of hospitalization was 15 days (SD ± 4.4). Twenty-seven patients (15.8%) showed lifetime psychotic symptoms, while forty-one patients (24.0%) had lifetime residual symptoms.
Most patients had psychiatric or medical comorbidities. A total of 90 patients (52.6%) had psychiatric comorbidities and 100 patients (58.5%) had medical comorbidities. About half of the patients were taking at least four medications (n = 69, 40.4%), whereas only 51 of them (29.8%) were undergoing non-pharmacological treatment. Finally, 21 patients (12.3%) had been admitted to the psychiatric ward for a suicide attempt and 70 patients (41.0%) reported a lifetime suicide attempt. All the sociodemographic and clinical characteristics are summarized in Table 1.

3.2. Correlation Analysis Between Hopelessnesss, Alexithymia, Rumination, Mind Wandering, and Sociodemographic and Clinical Characteristics

In our study, no significant correlation was found between the psychopathological and sociodemographic characteristics of our patients, whereas several positive associations with their novel clinical dimensions were observed. Patients with higher levels of hopelessness had more psychiatric (p = 0.04) and medical comorbidities (p = 0.03). Furthermore, these patients were more likely to have complex polypharmacotherapy (p = 0.02). On the other hand, the presence of alexithymia was positively associated with longer durations of hospitalization, particularly in patients with higher scores on the difficulties in externally oriented thinking subscale (p = 0.03), and psychiatric comorbidities, particularly in patients with higher scores for difficulties in identifying emotions (p = 0.01).
Specifically regarding rumination, this clinical dimension was significantly associated with the presence of residual symptoms (p = 0.04) and more psychiatric (p = 0.01) and medical comorbidities (p = 0.04), especially in those with higher scores in the depression subscale (p = 0.04). Furthermore, patients who scored higher in the RRS depression subscale were more likely to take at least four medications (p = 0.03). Moreover, a significant association between mind wandering and the presence of medical comorbidities (p = 0.02) was observed, particularly when it was more frequent (p = 0.04). Patients who scored higher in the subscale measuring deliberate mind wandering showed more residual symptoms (p = 0.03), especially when mind wandering was more frequent as measured by the DDFS (p = 0.02). Finally, no significant correlation was observed between suicidal behaviors (suicidal ideation and current/lifetime suicide attempts) and rumination or mind wandering. The only significant correlation was found between lifetime suicide attempts and higher levels of hopelessness (p = 0.01) (see Table 2).

3.3. Difference in Clinical Dimensions Investigated Between BD Type I and II

In our study, considering the difference between BD type I and II, no statistically relevant differences in rumination, mind wandering, or alexithymia were found. However, a feeling of hopelessness was more prevalent in patients with BD type II (Table 3).

4. Discussion

The findings of this research provide insights critical to better understanding the course of BD, its psychopathological manifestations, and the impact of several clinical dimensions not considered in the diagnostic criteria of the DSM 5-TR. Hopelessness, alexithymia, rumination, and mind wandering were investigated and correlated with the sociodemographic and clinical characteristics of patients with a primary diagnosis of BD. As expected, an equal gender distribution, an average age of 48 years, and a significant prevalence of psychiatric and medical comorbidities were found. Most patients were on complex polypharmacotherapy, with a notable portion also engaged in non-pharmacological treatment. Finally, a considerable number of patients had been previously hospitalized following a suicide attempt.
In the literature, it is well known that feelings of hopelessness are accepted as a transnosographic and transdiagnostic measure of increased risk for suicidal behaviors in psychiatric patients and the general population [39]. In our sample, a strong association was observed between high levels of hopelessness and the presence of psychiatric and medical comorbidities. The International Society for Bipolar Disorders (ISBD) task force on suicide summarized all the sociodemographic and clinical factors potentially associated with increased suicidal behaviors [40]. In particular, the presence of comorbid anxiety disorders, substance use disorders, or Cluster B personality disorders, especially borderline personality disorder, are considered risk factors for suicidal behaviors. Furthermore, these psychiatric comorbid conditions are known to exacerbate the severity of BD, potentially reflecting a more challenging and destabilizing clinical course [32,41,42]. From this point of view, it is not surprising that the feelings of hopelessness were notably higher in bipolar patients taking at least four medications, potentially indicative of a more difficult therapeutic challenge. Though direct evidence from the literature is limited, a greater pharmacological burden may contribute to patients’ feelings of despair regarding their psychopathological condition of mood instability. The exact causality remains unclear, but the literature suggests that comorbid conditions may either signal a more severe bipolar picture or contribute to increased ruminative thinking, which is closely linked to suicidal ideation [43,44]. For example, patients with comorbid anxiety disorders may experience heightened ruminative thoughts centered on suicidal behavior, while substance use disorders may amplify impulsivity, further increasing risk [45,46]. Additionally, prolonged psychiatric hospitalization was associated with higher levels of alexithymia, particularly in the externally oriented thinking (EOT) domain. This may reflect the impact of protracted inpatient care on patients’ socioemotional functioning [47].
Rumination and mind wandering were positively correlated with psychiatric and medical comorbidities, as well as residual symptoms. These transdiagnostic phenomena are increasingly recognized as key contributors to the co-occurrence of symptoms across disorders, particularly in mood disorders [48,49]. Excessive rumination, especially, has been identified as a common feature in both depressive and manic episodes [22,50], suggesting its pivotal role in BD. While studied less extensively in BD compared to unipolar depression, the interplay between rumination and hopelessness warrants further attention. Both constructs appear to perpetuate a vicious cycle, amplifying negative effects and hindering emotional regulation. Therefore, enhancing patients’ capacity to regulate intrusive and ruminative thoughts may hold promise for preventing both depressive and manic episodes [51,52]. Recently, the number of previous suicide attempts was significantly correlated with scores for reflective ponderings, brooding, and global rumination in patients with BD. Furthermore, hopelessness and rumination were correlated [53].
Although no direct correlations between rumination or mind wandering and suicidal ideation or suicide attempts were observed in this study, patients with higher levels of hopelessness were significantly more likely to have attempted suicide. This aligns with the existing literature that identifies hopelessness as a transdiagnostic measure associated with increased suicide risk [12,53,54]. Hopelessness exacerbates feelings of pessimism about the future, serving as an independent factor for increased suicide risk, and patients with a history of suicide attempts exhibit higher hopelessness scores; furthermore, they often present comorbid anxiety disorders [55]. Interestingly, patients with BD type II demonstrated higher levels of hopelessness compared to those with BD type I. This is quite expected, because patients with a primary diagnosis of BD type II usually reported more severe and longer major depressive episodes, presenting unique challenges in the evaluation and management of depression within this subtype, higher antidepressant usage, and an unstable illness course [56,57]. Furthermore, major depressive episodes are usually associated with comorbidities (especially in BD type II), with greater disability and a worse quality of life [58] often accompanied by elevated hopelessness and strongly linked to increased suicidal behavior [59].
The relationship between insight, hopelessness, and suicidal risk has also been explored in the literature, particularly within the proposed “insight-demotivation-depression-suicidality” syndrome [60]. In BD, the interplay between hopelessness, psychiatric comorbidities, and emotional dysregulation may reflect a similar phenomenon, further underscoring the importance of targeted interventions. Chronicity, global impairment, and the persistence of residual symptoms despite comprehensive pharmacological treatment highlight the need for multifaceted therapeutic approaches [61,62]. It is well known that suicide risk is notably higher in depressive mixed states of BD compared to manic, depressive, or euthymic phases [63,64,65]. From a clinical perspective, our findings underline the need for greater attention to residual symptoms, suicidal behaviors, and psychiatric or medical comorbidities in patients with BD. As a matter of fact, these clinical factors lead not only to a worse outcome in terms of quality of life and functioning, but also to higher reported levels of hopelessness, alexithymia, mind wandering, and rumination. These patients often represent more complex clinical cases, characterized by frequent hospitalizations, a more severe illness trajectory, and an increased risk of suicidal behaviors [12,22,32,40,53]. Despite the clinical relevance of these psychopathological dimensions, current guidelines do not provide specific recommendations for managing these transdiagnostic features in patients with BD. Our findings highlight the importance of structured, personalized interventions to treat these psychological vulnerabilities. For example, in cases of rumination and hopelessness, the use of antidepressants could be avoided in favor of specific non-pharmacological interventions, such as structured psychoeducation and enhanced family support, to improve patient outcomes and functional recovery. These insights support a shift toward individualized care in BD, moving beyond syndromic classifications and focusing on the broader psychopathological profile of each patient.

5. Limitations

The present study was preliminary and exploratory due to the limited literature on this topic. Despite the clinical relevance of our findings, this study has certain limitations that should be discussed. First, the study had a cross-sectional design, limiting statements regarding causality or the directionality of the associations observed due to the lack of follow-up data. Further longitudinal studies are warranted to clarify the temporal relationships between hopelessness, alexithymia, rumination, mind wandering, and clinical outcomes in individuals with BD. Secondly, the novel clinical dimensions, such as hopelessness, alexithymia, rumination, and mind wandering, were evaluated by self-rated scales, with potential response biases like social desirability and recall bias due to the intrinsic nature of self-reporting. Future research should consider incorporating multi-method assessment strategies, such as clinician-administered psychometric tools, observer-rated scales, and biological or behavioral measures, to improve the reliability and validity of the findings. Third, our sample was relatively small, including only inpatients from a single psychiatric unit and considering only severe cases, which may limit the generalizability of the results to the broader bipolar population, particularly outpatients or individuals with less severe presentations. Future studies should aim to include larger and more heterogeneous samples to enhance external validity and provide more representative data. Additionally, the study involved multiple statistical comparisons without applying correction methods such as Bonferroni adjustment or False Discovery Rate control. While this approach aligns with the exploratory intent of the analysis, it increases the risk of type I errors. These results should be interpreted with caution and validated in future longitudinal research using appropriate designs and appropriate statistical correction strategies.

6. Conclusions

The significant correlation between novel clinical dimensions, comorbidities, and suicidal behaviors highlights the critical need for clinicians to assess and address these factors in their daily clinical practice. Importantly, hopelessness, alexithymia, mind wandering, and rumination should be identified as important proxies of impaired subjective well-being that should be carefully monitored because they could further worsen the clinical course of BD and suicidal risk in this vulnerable population.
Further, longitudinal studies are needed to replicate our preliminary and exploratory results and may further help to ameliorate the destabilizing course of BD, implement appropriate and personalized non-pharmacological strategies, and discover more solid links, affirming the importance of these factors in order to increase the quality of life, extend the psychophysical well-being, and promote the functional recovery of patients with BD.

Author Contributions

Conceptualization, A.A. (Andrea Aguglia), T.C., and M.R.; methodology, S.I. and M.R.; validation, M.A. and G.S.; formal analysis, T.C.; investigation, S.I., F.B. (Francesco Bruni), and F.B. (Francesca Bigiotti); data curation, S.I., F.B. (Francesco Bruni), and F.B. (Francesca Bigiotti); writing—original draft preparation, T.C. and A.A. (Andrea Aguglia).; writing—review and editing, A.C. and A.A. (Andrea Amerio); supervision, M.A. and G.S.; project administration, A.A. (Andrea Aguglia). All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of IRCCS Ospedale Policlinico San Martino.

Informed Consent Statement

Written informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy/ethical restrictions.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
BD type IBipolar Disorder type I
BD type IIBipolar Disorder type II
BHSBeck Hopelessness Scale
RRSRuminative Response Scale
TASToronto Alexithymia Scale
MWQMind Wandering Questionnaire
MWDMind Wandering Deliberate
MWSMind Wandering Spontaneous
DDFSDaydreaming Frequency Scale
SDStandard deviation

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders—Fifth Edition, Text Revised (DSM 5-TR); American Psychiatric Publishing: Washington, DC, USA, 2022. [Google Scholar]
  2. Mcgrath, J.J.; Al-Hamzawi, A.; Alonso, J.; Altwaijri, Y.; Andrade, L.H.; Bromet, E.J.; Bruffaerts, R.; Caldas de Almeida, J.M.; Chardoul, S.; Chiu, W.T.; et al. Age of onset and cumulative risk of mental disorders: A cross-national analysis of population surveys from 29 countries. Lancet Psychiatry 2023, 10, 668–681. [Google Scholar] [CrossRef] [PubMed]
  3. Krishnan, K.R. Psychiatric and medical comorbidities of bipolar disorder. Psychosom. Med. 2005, 67, 1–8. [Google Scholar] [CrossRef] [PubMed]
  4. Golden, J.C.; Goethe, J.W.; Woolley, S.B. Complex psychotropic polypharmacy in bipolar disorder across varying mood polarities: A prospective cohort study of 2712 inpatients. J. Affect. Disord. 2017, 221, 6–10. [Google Scholar] [CrossRef]
  5. Kim, A.M.; Salstein, L.; Goldberg, J.F. A systematic review of complex polypharmacy in bipolar disorder: Prevalence, clinical features, adherence, and preliminary recommendations for practitioners. J. Clin. Psychiatry 2021, 82, 20r13263. [Google Scholar] [CrossRef]
  6. Aguglia, A.; Natale, A.; Fusar-Poli, L.; Amerio, A.; Costanza, A.; Fesce, F.; Gnecco, G.B.; Marino, M.; Placenti, V.; Serafini, G.; et al. Complex polypharmacy in bipolar disorder: Results from a real-world inpatient psychiatric unit. Psychiatry Res. 2022, 318, 114927. [Google Scholar] [CrossRef] [PubMed]
  7. Salvi, V.; Aguglia, A.; Barone-Adesi, F.; Bianchi, D.; Donfrancesco, C.; Dragogna, F.; Palmieri, L.; Serafini, G.; Amore, M.; Mencacci, C. Cardiovascular risk in patients with severe mental illness in Italy. Eur. Psychiatry 2020, 63, e96. [Google Scholar] [CrossRef]
  8. Biazus, T.B.; Beraldi, G.H.; Tokeshi, L.; Rotenberg, L.S.; Dragioti, E.; Carvalho, A.F.; Solmi, M.; Lafer, B. All-cause and cause-specific mortality among people with bipolar disorder: A large-scale systematic review and meta-analysis. Mol. Psychiatry 2023, 28, 2508–2524. [Google Scholar] [CrossRef]
  9. Trott, M.; Suetani, S.; Arnautovska, U.; Kisely, S.; Kar Ray, M.; Theodoros, T.; Le, V.; Leske, S.; Lu, M.; Soole, R.; et al. Suicide methods and severe mental illness. A systematic review and meta-analysis. Acta Psychiatr. Scand. 2025, 151, 467–484. [Google Scholar] [CrossRef]
  10. Valtonen, H.M.; Suominen, K.; Haukka, J.; Mantere, O.; Arvilommi, P.; Leppämäki, S.; Isometsä, E.T. Hopelessness across phases of bipolar I or II disorder: A prospective study. J. Affect. Disord. 2009, 115, 11–17. [Google Scholar] [CrossRef]
  11. Costanza, A.; Amerio, A.; Aguglia, A.; Escelsior, A.; Serafini, G.; Berardelli, I.; Pompili, M.; Amore, M. When Sick Brain and Hopelessness Meet: Some Aspects of Suicidality in the Neurological Patient. CNS Neurol. Disord. Drug Targets 2020, 19, 257–263. [Google Scholar] [CrossRef]
  12. Serafini, G.; Lamis, D.A.; Aguglia, A.; Amerio, A.; Nebbia, J.; Geoffroy, P.A.; Pompili, M.; Amore, M. Hopelessness and its correlates with clinical outcomes in an outpatient setting. J. Affect. Disord. 2020, 263, 472–479. [Google Scholar] [CrossRef] [PubMed]
  13. Acosta, F.J.; Vega, D.; Torralba, L.; Navarro, S.; Ramallo-Fariña, Y.; Fiuza, D.; Hernández, J.L.; Siris, S.G. Hopelessness and suicidal risk in bipolar disorder. A study in clinically nonsyndromal patients. Compr. Psychiatry 2012, 53, 1103–1109. [Google Scholar] [CrossRef] [PubMed]
  14. Palagini, L.; Miniati, M.; Marazziti, D.; Sharma, V.; Riemann, D. Association among early life stress, mood features, hopelessness and suicidal risk in bipolar disorder: The potential contribution of insomnia symptoms. J. Psychiatr. Res. 2021, 135, 52–59. [Google Scholar] [CrossRef] [PubMed]
  15. Ospina, L.H.; Shanahan, M.; Perez-Rodriguez, M.M.; Chan, C.C.; Clari, R.; Burdick, K.E. Alexithymia predicts poorer social and everyday functioning in schizophrenia and bipolar disorder. Psychiatry Res. 2019, 273, 218–226. [Google Scholar] [CrossRef]
  16. Dou, W.; Yu, X.; Fang, H.; Lu, D.; Cai, L.; Zhu, C.; Zong, K.; Zheng, Y.; Lin, X. Family and Psychosocial Functioning in Bipolar Disorder: The Mediating Effects of Social Support, Resilience and Suicidal Ideation. Front. Psychol. 2022, 12, 807546. [Google Scholar] [CrossRef]
  17. Takım, U.; Sarı, S.; Gokcay, H. The Relationship Between Childhood Traumas and Social Cognition Through Theory of Mind and Alexithymia in Bipolar Disorder. Psychol. Rep. 2025, 128, 800–815. [Google Scholar] [CrossRef]
  18. Khosravani, V.; Berk, M.; Sharifi Bastan, F.; Samimi Ardestani, S.M.; Wrobel, A. The effects of childhood emotional maltreatment and alexithymia on depressive and manic symptoms and suicidal ideation in females with bipolar disorder: Emotion dysregulation as a mediator. Int. J. Psychiatry Clin. Pract. 2021, 25, 90–102. [Google Scholar] [CrossRef]
  19. Ayık, B.; Baş, A.; Usta Sağlam, N.G.; İzci, F. The Relationship Between Emotional Dysregulation, Alexithymia and Somatization in Patients with Bipolar Disorder. Alpha Psychiatry 2023, 24, 15–21. [Google Scholar] [CrossRef]
  20. Yang, J.; Wang, L.; Jin, C.; Wu, Y.W.; Zhao, K. The Bridge Between Childhood Trauma and Alexithymia Among Adolescents with Depressive and Bipolar Disorders: A Network Bridge Analysis. Child Psychiatry Hum. Dev. 2024. Epub ahead of print. [Google Scholar] [CrossRef]
  21. Nolen-Hoeksema, S.; Wisco, B.E.; Lyubomirsky, S. Rethinking rumination. Perspect. Psychol. Sci. 2008, 3, 400–424. [Google Scholar] [CrossRef]
  22. Kovács, L.N.; Takacs, Z.K.; Tóth, Z.; Simon, E.; Schmelowszky, Á.; Kökönyei, G. Rumination in major depressive and bipolar disorder—A meta-analysis. J. Affect. Disord. 2020, 276, 1131–1141. [Google Scholar] [CrossRef]
  23. Aslan, I.H.; Baldwin, D.S. Ruminations and their correlates in depressive episodes: Between-group comparison in patients with unipolar or bipolar depression and healthy controls. J. Affect. Disord. 2021, 280 Pt A, 1–6. [Google Scholar] [CrossRef] [PubMed]
  24. Silveira, É.d.M.; Kauer-Sant’Anna, M. Rumination in bipolar disorder: A systematic review. Braz. J. Psychiatry 2015, 37, 256–263. [Google Scholar] [CrossRef]
  25. Smallwood, J.; Schooler, J.W. The science of mind wandering: Empirically navigating the stream of consciousness. Annu. Rev. Psychol. 2015, 66, 487–518. [Google Scholar] [CrossRef]
  26. Marchetti, I.; Koster, E.H.W.; Klinger, E.; Alloy, L.B. Spontaneous Thought and Vulnerability to Mood Disorders: The Dark Side of the Wandering Mind. Clin. Psychol. Sci. 2016, 4, 835–857. [Google Scholar] [CrossRef] [PubMed]
  27. Nayda, D.M.; Takarangi, M.K.T. The cost of being absent: Is meta-awareness of mind-wandering related to depression symptom severity, rumination tendencies and trauma intrusions? J. Affect. Disord. 2021, 292, 131–138. [Google Scholar] [CrossRef]
  28. Tang, H.; Xiong, T.; Shi, J.; Chen, Y.; Liu, X.; Zhang, S.; Wang, H.; Lu, Q.; Yao, Z. Global and reflective rumination are related to suicide attempts among patients experiencing major depressive episodes. BMC Psychiatry 2021, 21, 117. [Google Scholar] [CrossRef]
  29. Liu, D.; Lei, G.; Li, D.; Deng, H.; Zhang, X.Y.; Dang, Y. Depression, Rumination, and Suicide Attempts in Adolescents with Mood Disorders: Sex Differences in This Relationship. J. Clin. Psychiatry 2024, 85, 23m15136. [Google Scholar] [CrossRef] [PubMed]
  30. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013, 310, 2191–2194. [Google Scholar] [CrossRef]
  31. Aguglia, A.; Giacomini, G.; De Michiel, C.F.; Garbarino, N.; Lechiara, A.; Magni, C.; Meinero, M.; Verrina, E.; Costanza, A.; Amerio, A.; et al. Characterization of Bipolar Disorder I and II: Clinical Features, Comorbidities, and Pharmacological Pattern. Alpha Psychiatry 2024, 25, 472–479. [Google Scholar] [CrossRef]
  32. Aguglia, A.; Natale, A.; Fusar-Poli, L.; Amerio, A.; Bruno, E.; Placenti, V.; Vai, E.; Costanza, A.; Serafini, G.; Aguglia, E.; et al. Bipolar Disorder and Polysubstance Use Disorder: Sociodemographic and Clinical Correlates. Front. Psychiatry 2022, 13, 913965. [Google Scholar] [CrossRef]
  33. Beck, A.T. BHS, Beck Hopelessness Scale; Psychological Corp.: San Antonio, TX, USA; Harcourt Brace Jovanovich: New York, NY, USA, 1988. [Google Scholar]
  34. Bagby, R.M.; Taylor, G.J.; Parker, J.D. The Twenty-item Toronto Alexithymia Scale--II. Convergent, discriminant, and concurrent validity. J. Psychosom. Res. 1994, 38, 33–40. [Google Scholar] [CrossRef] [PubMed]
  35. Nolen-Hoeksema, S. Responses to depression and their effects on the duration of depressive episodes. J. Abnorm. Psychol. 1991, 100, 569–582. [Google Scholar] [CrossRef] [PubMed]
  36. Treynor, W.; Gonzalez, R.; Nolen-Hoeksema, S. Rumination reconsidered: A psychometric analysis. Cogn. Ther. Res. 2003, 27, 247–259. [Google Scholar] [CrossRef]
  37. Gionet, S.; Arseneau, J.; Plourde, V. Psychopathology and mind wandering in young university students. J. Psychiatr. Res. 2023, 163, 350–356. [Google Scholar] [CrossRef]
  38. Mrazek, M.D.; Philips, D.T.; Franklin, M.S.; Broadway, J.M.; Schooler, J.W. Young and restless: Validation of the Mind-Wandering Questionnaire (MWQ) reveals disruptive impact of mind-wandering for youth. Front. Psychol. 2013, 4, 560. [Google Scholar] [CrossRef] [PubMed]
  39. Klonsky, E.D.; May, A.M.; Saffer, B.Y. Suicide, Suicide Attempts, and Suicidal Ideation. Annu. Rev. Clin. Psychol. 2016, 12, 307–330. [Google Scholar] [CrossRef]
  40. Schaffer, A.; Isometsa, E.T.; Tondo, L.; Moreno, D.H.; Turecki, G.; Reis, C.; Cassidy, F.; Sinyor, M.; Azorin, J.M.; Kessing, L.V.; et al. International society for bipolar disorders task force on suicide: Meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord. 2015, 17, 1–16. [Google Scholar] [CrossRef]
  41. Carra, G.; Bartoli, F.; Crocamo, C.; Brady, K.T.; Clerici, M. Attempted suicide in people with cooccurring bipolar and substance use disorders: Systematic review and meta-analysis. J. Affect. Disord. 2014, 167, 125–135. [Google Scholar] [CrossRef]
  42. de Filippis, R.; Aguglia, A.; Costanza, A.; Benatti, B.; Placenti, V.; Vai, E.; Bruno, E.; De Berardis, D.; Dell’Osso, B.; Albert, U.; et al. Obsessive-Compulsive Disorder as an Epiphenomenon of Comorbid Bipolar Disorder? An Updated Systematic Review. J. Clin. Med. 2024, 13, 1230. [Google Scholar] [CrossRef]
  43. Simon, N.M.; Zalta, A.K.; Otto, M.W.; Ostacher, M.J.; Fischmann, D.; Chow, C.W.; Thompson, E.H.; Stevens, J.C.; Demopulos, C.M.; Nierenberg, A.A.; et al. The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. J. Psychiatr. Res. 2007, 41, 255–264. [Google Scholar] [CrossRef]
  44. Perroud, N.; Baud, P.; Preisig, M.; Etain, B.; Bellivier, F.; Favre, S.; Reber, N.; Ferrero, F.; Leboyer, M.; Malafosse, A. Social phobia is associated with suicide attempt history in bipolar inpatients. Bipolar Disord. 2007, 9, 713–721. [Google Scholar] [CrossRef] [PubMed]
  45. Maser, J.D.; Akiskal, H.S.; Schettler, P.; Scheftner, W.; Mueller, T.; Endcott, J.; Solomon, D.; Clayton, P. Can temperament identify affectively ill patients who engage in lethal or near-lethal suicidal behavior? A 14-year prospective study. Suicide Life Threat. Behav. 2002, 32, 10–32. [Google Scholar] [CrossRef] [PubMed]
  46. Nakagawa, A.; Grunebaum, M.F.; Sullivan, G.M.; Currier, D.; Ellis, S.P.; Burke, A.K.; Brent, D.A.; Mann, J.J.; Oquendo, M.A. Comorbid anxiety in bipolar disorder: Does it have an independent effect on suicidality? Bipolar Disord. 2008, 10, 530–538. [Google Scholar] [CrossRef]
  47. De Abreu, L.N.; Nery, F.G.; Harkavy-Friedman, J.M.; de Almeida, K.M.; Gomes, B.C.; Oquendo, M.A.; Lafer, B. Suicide attempts are associated with worse quality of life in patients with bipolar disorder type I. Compr. Psychiatry 2012, 53, 125–129. [Google Scholar] [CrossRef]
  48. Mattila, A.K.; Saarni, S.I.; Salminen, J.K.; Huhtala, H.; Sintonen, H.; Joukamaa, M. Alexithymia and health-related quality of life in a general population. Psychosomatics 2009, 50, 59–68. [Google Scholar] [CrossRef]
  49. McLaughlin, K.A.; Aldao, A.; Wisco, B.E.; Hilt, L.M. Rumination as a transdiagnostic factor underlying transitions between internalizing symptoms and aggressive behavior in early adolescents. J. Abnorm. Psychol. 2014, 123, 13–23. [Google Scholar] [CrossRef] [PubMed]
  50. Johnson, S.L.; McKenzie, G.; McMurrich, S. Ruminative responses to negative and positive affect among students diagnosed with bipolar disorder and major depressive disorder. Cognit. Ther. Res. 2008, 32, 702–713. [Google Scholar] [CrossRef]
  51. Berking, M.; Wupperman, P.; Reichardt, A.; Pejic, T.; Dippel, A.; Znoj, H. Emotion-regulation skills as a treatment target in psychotherapy. Behav. Res. Ther. 2008, 46, 1230–1237. [Google Scholar] [CrossRef]
  52. Townsend, J.; Altshuler, L.L. Emotion processing and regulation in bipolar disorder: A review. Bipolar Disord. 2012, 14, 326–339. [Google Scholar] [CrossRef]
  53. Aydın, E.F.; Özcan, H.; Yılmaz, S.; Aşkın, S.; Koca Laçin, T.; Topu, E.N. Homocysteine, hopelessness, rumination, affective temperaments, and clinical course in patients with bipolar disorder-1. Nord. J. Psychiatry 2024, 78, 465–476. [Google Scholar] [CrossRef]
  54. Sánchez-Moreno, J.; Martínez-Aran, A.; Tabarés-Seisdedos, R.; Torrent, C.; Vieta, E.; Ayuso-Mateos, J.L. Functioning and disability in bipolar disorder: An extensive review. Psychother. Psychosom. 2009, 78, 285–297. [Google Scholar] [CrossRef]
  55. Klonsky, D.E.; Kotov, R.; Bakst, S.; Rabinowitz, J.; Bromet, E.J. Hopelessness as a predictor of attempted suicide among first admission patients with psychosis: A 10-year cohort study. Suicide Life Threat. Behav. 2012, 42, 1–10. [Google Scholar] [CrossRef] [PubMed]
  56. Baldessarini, R.J.; Salvatore, P.; Kaur Khalsa, H.M.; Gebre-Medhin, P.; Imaz, H.; Gonzales-Pinto, A.; Perez, J.; Cruz, N.; Maggini, C.; Tohen, M. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord. 2010, 12, 264–270. [Google Scholar] [CrossRef] [PubMed]
  57. Au, J.S.; Martinez de Andino, A.; Mekawi, Y.; Silverstein, M.V.; Lamis, D.A. Latent class analysis of bipolar disorder symptoms and suicidal ideation and behaviors. Bipolar Disord. 2021, 23, 86–95. [Google Scholar] [CrossRef]
  58. Tondo, L.; Vázquez, G.H.; Pinna, M.; Vaccotto, P.A.; Baldessarini, R.J. Characteristics of depressive and bipolar patients with mixed features. Acta Psychiatr. Scand. 2018, 138, 243–252. [Google Scholar] [CrossRef]
  59. Isometsä, E.T.; Henriksson, M.M.; Aro, H.M.; Lonnqvist, J.K. Suicide in bipolar disorder in Finland. Am. J. Psychiatry 1994, 151, 1020–1024. [Google Scholar] [CrossRef]
  60. Valtonen, H.M.; Suominen, K.; Haukka, J.; Mantere, O.; Leppämäki, S.; Arvilommi, S.; Isometsä, E.T. Differences in incidence of suicide attempts during phases of bipolar I and II disorders. Bipolar Disord. 2008, 10, 588–596. [Google Scholar] [CrossRef] [PubMed]
  61. Burdick, K.E.; Goldberg, J.F.; Harrow, M. Neurocognitive dysfunction and psychosocial outcome in patients with bipolar I disorder at 15-year follow-up. Acta Psychiatr. Scand. 2010, 122, 499–506. [Google Scholar] [CrossRef]
  62. Goldberg, J.F.; Harrow, M. A 15-year prospective follow-up of bipolar affective disorders: Comparisons with unipolar nonpsychotic depression. Bipolar Disord. 2011, 13, 155–163. [Google Scholar] [CrossRef]
  63. Valtonen, H.M.; Suominen, K.; Mantere, O.; Leppämäki, S.; Arvilommi, P.; Isometsä, E. Suicidal behaviour during different phases of bipolar disorder. J. Affect. Disord. 2007, 97, 101–107. [Google Scholar] [CrossRef]
  64. Halfon, N.; Labelle, R.; Cohen, D.; Guilè, J.M.; Breton, J.J. Juvenile bipolar disorder and suicidality: A review of the last 10 years of literature. Eur. Child Adolesc. Psychiatry 2013, 22, 139–151. [Google Scholar] [CrossRef] [PubMed]
  65. Mineo, L.; Rodolico, A.; Spedicato, G.A.; Aguglia, A.; Bolognesi, S.; Concerto, C.; Cuomo, A.; Goracci, A.; Maina, G.; Fagiolini, A.; et al. Exploration of mood spectrum symptoms during a major depressive episode: The impact of contrapolarity-Results from a transdiagnostic cluster analysis on an Italian sample of unipolar and bipolar patients. Eur. Psychiatry 2022, 65, e30. [Google Scholar] [CrossRef] [PubMed]
Table 1. Sociodemographic and clinical characteristics of total sample.
Table 1. Sociodemographic and clinical characteristics of total sample.
N (%) or Mean ± SDTotal Sample (n = 171)
Sociodemographic characteristics
Gender, female, N (%)86 (50.3)
Current age in years48 ± 14
Marital status
     Single
     Married
     Divorced/separated
     Widowed
116 (68.3)
29 (17.0)
24 (14.3)
1 (0.4)
Educational level in years11.6 ± 3.3
Italian nationality151 (88.4)
Occupational status, employed69 (40.2)
Living with
     Alone
     Family
     Residence
62 (36.6)
105 (61.3)
4 (2.1)
Clinical characteristics
Length of hospitalization in days15 ± 4.4
Age onset in years27 ± 11
Illness duration in years21 ± 13
Suicidal ideation76 (44.7)
Suicide attempts
     Current
     Lifetime
21 (12.3)
70 (41.0)
At least one psychiatric comorbidity90 (52.6)
At least one medical comorbidity100 (58.5)
Lifetime psychotic symptoms27 (15.8)
Lifetime residual symptoms41 (24.0)
Complex polypharmacotherapy69 (40.4)
Non-pharmacological treatment51 (29.8)
Table 2. Linear correlation between clinical characteristics and psychopathological dimensions investigated.
Table 2. Linear correlation between clinical characteristics and psychopathological dimensions investigated.
Rho Length of
Hospitalization		Psychiatric ComorbidityMedical ComorbidityComplex
Pharmacotherapy		Residual SymptomsLifetime
Suicide Attempts
p
BHS tot−0.0908
0.85		0.151
0.0419		0.167
0.025		0.172
0.022		0.094
0.14		0.245
<0.01
RRS tot0.0074
0.46		0.213
<0.01		0.149
0.0405		0.066
0.221		0.151
0.0404		0.02
0.41
RRS
depression		−0.016
0.57		0.0784
0.18		0.148
0.0421		0.156
0.034		0.113
0.096		0.022
0.40
RRS
reflection		−0.0207
0.59		0.0507
0.27		0.134
0.0588		0.0194
0.41		0.11
0.10		0.09
0.15
TAS dif−0.133
0.93		0.196
<0.01		−0.0682
0.78		0.0959
0.13		−0.115
0.91		0.127
0.07
TAS eot0.162
0.0316		−0.109
0.55		−0.129
0.93		−0.003
0.502		−0.073
0.79		0.025
0.38
MWQ tot−0.00009
0.54		0.0766
0.18		0.182
<0.01		0.071
0.203		0.097
0.13		0.056
0.26
MWD tot−0.0785
0.81		−0.0135
0.56		0.105
0.11		0.084
0.16		0.165
0.0279		0.104
0.12
DDFS tot−0.0192
0.58		0.0584
0.24		0.148
0.0418		0.061
0.24		0.183
<0.01		0.057
0.26
BHS: Beck Hopelessness Scale; RRS: Ruminative Response Scale; TAS: Toronto Alexithymia Scale; MWQ: Mind Wandering Questionnaire; MW.D: Mind Wandering Deliberate; MW.S: Mind Wandering Spontaneous; DDFS: Daydreaming Frequency Scale.
Table 3. Difference in clinical dimensions investigated between BD type I and II.
Table 3. Difference in clinical dimensions investigated between BD type I and II.
Mean ± SDBD Type IBD Type IIp
BHS tot5.18 ± 4.127.41 ± 5.550.02
RRS tot33.91 ± 22.4738.98 ± 27.310.29
RRS depression9.67 ± 5.198.86 ± 5.040.14
RRS reflection7.96 ± 4.358.86 ± 5.040.84
RRS brooding16.61 ± 10.0719 ± 12.490.27
TAS tot41.31 ± 20.2143.39 ± 22.530.61
TAS level4.26 ± 6.054.41 ± 5.780.89
TAS ddf13.07 ± 3.9614.52 ± 5.280.11
TAS dif16.61 ± 7.6916.98 ± 7.550.79
TAS eot26.33 ± 1326.07 ± 12.790.91
MWQ tot11.91 ± 8.3712.36 ± 8.980.78
MWD tot10.37 ± 8.319.14 ± 6.860.39
MWS tot11.35 ± 7.9810.61 ± 8.670.64
DDFS tot21.72 ± 16.1921.36 ± 16.060.91
BD type I: Bipolar Disorder type I; BD type II: Bipolar Disorder type 2; BHS: Beck Hopelessness Scale; RRS: Ruminative Response Scale; TAS: Toronto Alexithymia Scale; MWQ: Mind Wandering Questionnaire; MW.D: Mind Wandering Deliberate; MW.S: Mind Wandering Spontaneous; DDFS: Daydreaming Frequency Scale.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Aguglia, A.; Cerisola, T.; Rimondotto, M.; Iannini, S.; Bruni, F.; Bigiotti, F.; Costanza, A.; Amore, M.; Amerio, A.; Serafini, G. Investigating the Relationship Between Hopelessness, Alexithymia, Mind Wandering, Rumination, and Clinical Features in Patients with Bipolar Disorder. Brain Sci. 2025, 15, 596. https://doi.org/10.3390/brainsci15060596

AMA Style

Aguglia A, Cerisola T, Rimondotto M, Iannini S, Bruni F, Bigiotti F, Costanza A, Amore M, Amerio A, Serafini G. Investigating the Relationship Between Hopelessness, Alexithymia, Mind Wandering, Rumination, and Clinical Features in Patients with Bipolar Disorder. Brain Sciences. 2025; 15(6):596. https://doi.org/10.3390/brainsci15060596

Chicago/Turabian Style

Aguglia, Andrea, Tommaso Cerisola, Martina Rimondotto, Simona Iannini, Francesco Bruni, Francesca Bigiotti, Alessandra Costanza, Mario Amore, Andrea Amerio, and Gianluca Serafini. 2025. "Investigating the Relationship Between Hopelessness, Alexithymia, Mind Wandering, Rumination, and Clinical Features in Patients with Bipolar Disorder" Brain Sciences 15, no. 6: 596. https://doi.org/10.3390/brainsci15060596

APA Style

Aguglia, A., Cerisola, T., Rimondotto, M., Iannini, S., Bruni, F., Bigiotti, F., Costanza, A., Amore, M., Amerio, A., & Serafini, G. (2025). Investigating the Relationship Between Hopelessness, Alexithymia, Mind Wandering, Rumination, and Clinical Features in Patients with Bipolar Disorder. Brain Sciences, 15(6), 596. https://doi.org/10.3390/brainsci15060596

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop